作者
Stefanos Bonovas, Silvia Minozzi, Theodore Lytras, Marien Gonzalez-Lorenzo, Valentina Pecoraro, Silvia Colombo, Ilaria Polloni, Lorenzo Moja, Michela Cinquini, Valentina Marino, Delia Goletti, Andrea Matucci, Giuliano Tocci, Giuseppe Maria Milano, Raffaele Scarpa, Fabrizio Cantini
发表日期
2016/12/5
来源
Expert opinion on drug safety
卷号
15
期号
sup1
页码范围
35-54
出版商
Taylor & Francis
简介
Introduction: Malignancies have been reported in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, treated with anti-tumour necrosis factor (anti-TNF) agents.
Areas covered: We conducted a systematic review of randomized controlled trials (RCTs) to determine the effect of anti-TNF agents on the occurrence of cancer (any type). Literature databases were searched up to May 2014 to identify relevant studies that evaluated adalimumab, certolizumab, etanercept, golimumab, or infliximab, compared with placebo or no treatment. Data on cancer occurrence were extracted at the maximum follow-up time reported.
Expert opinion: Fifty-five RCTs with 20,631 patients met the eligibility criteria. Of these, 32 trials with 15,539 patients reported at least one case of cancer, for a total of 112 malignancies. The degree of variability between studies was consistent with what would be expected to occur by …
学术搜索中的文章
S Bonovas, S Minozzi, T Lytras, M Gonzalez-Lorenzo… - Expert opinion on drug safety, 2016
